Jin Medicine Co., Ltd. (CEO Yoon Chae-ok) announced that it will participate in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
Gene Medicine is a biotech company that has developed an anti-cancer adenovirus drug for the treatment of intractable cancer that can be administered systemically. It is known that a total of four products are under development, including the pipeline ‘GM 1’, which has shown strong tumor-specific antitumor effects, excellent stability, and efficacy in preclinical trials and phase 101 clinical trials.
In addition, we have a Drug Delivery System (DDS) that enhances the local and systemic delivery efficacy of anticancer viruses and gene therapy through delivery systems and material technologies, and we are also providing CDMO and CMO services specialized for viral vectors. .
In this exhibition, Gene Medicine will introduce a total of four types of its anti-cancer adenovirus pipeline, GM 101-104. The company explained that these pipelines, which have excellent tumor selectivity and replication capacity, activate anti-tumor immune responses and minimize systemic toxicity, ultimately exert strong therapeutic effects.
The CDMO/CMO service introduced together is characterized by being integrated into a one-stop service that solves everything from R&D (research and development) ideas to sample production and supply for clinical trials. Gene Medicine emphasized that it can produce a wide range of GMP gene therapy products to be applied to clinical trials, and provides high economic feasibility and productivity in gene and cell therapy research.
An official from Gene Medicine said, “We are planning to leap forward as a CDMO company specializing in viral vectors beyond the current business field established with confidence in commercialization.” There are very few companies in the world that have facilities for this. If we achieve our goal, we will have a competitive edge that can stand shoulder to shoulder with existing global companies.”
“Moreover, we want to establish a virtuous cycle structure in which profits generated from the CDMO business are invested in new drug development, and our goal is to improve the speed of clinical development as we have secured our own GMP facility,” he added.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.